Ignite Creation Date:
2025-12-24 @ 6:55 PM
Ignite Modification Date:
2026-02-22 @ 7:07 AM
Study NCT ID:
NCT05051657
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-11-28
First Post:
2021-09-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Evaluation of the Express Plus Range
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D010661', 'term': 'Phenylketonurias'}, {'id': 'D006712', 'term': 'Homocystinuria'}, {'id': 'D008375', 'term': 'Maple Syrup Urine Disease'}, {'id': 'D020176', 'term': 'Tyrosinemias'}, {'id': 'C536833', 'term': 'Glutaric Acidemia I'}], 'ancestors': [{'id': 'D020739', 'term': 'Brain Diseases, Metabolic, Inborn'}, {'id': 'D001928', 'term': 'Brain Diseases, Metabolic'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D000592', 'term': 'Amino Acid Metabolism, Inborn Errors'}, {'id': 'D008661', 'term': 'Metabolism, Inborn Errors'}, {'id': 'D030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D020138', 'term': 'Hyperhomocysteinemia'}, {'id': 'D003240', 'term': 'Connective Tissue Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE', 'maskingDescription': 'No masking, product will be given open label'}, 'primaryPurpose': 'SUPPORTIVE_CARE', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'single group - all patients to receive relevant express plus product'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 28}}, 'statusModule': {'overallStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2021-06-14', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-11', 'completionDateStruct': {'date': '2025-12-31', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-11-26', 'studyFirstSubmitDate': '2021-09-10', 'studyFirstSubmitQcDate': '2021-09-20', 'lastUpdatePostDateStruct': {'date': '2025-11-28', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2021-09-21', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-09-30', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Questionnaire of self-reported adherence to the prescribed amount of study product', 'timeFrame': 'Days 1-28', 'description': 'Participants will record the amount of PKU express taken each day compared to the amount recommended by their dietitian'}, {'measure': 'Transition time', 'timeFrame': 'Transition period Weeks 1-6 (maximum)', 'description': 'Time taken for participants to transition from their current diet to the inclusion of one sachet of PKU express plus per day'}, {'measure': 'Change in gastrointestinal tolerance from week 1 to week 4', 'timeFrame': 'Days 1-7 and days 21-28', 'description': 'Participants will self-report any gastrointestinal symptoms experience over the course of the study in daily study diaries'}, {'measure': 'Product acceptability rated on a Likert scale by the patient after 28-day intake', 'timeFrame': 'Visit 2 (end of 28 day evaluation period)', 'description': "Participants will answer questions relating to PKU express plus' palatability and ease of use following the end of study"}, {'measure': 'Change in general neophobia', 'timeFrame': 'Visit 1 (Day 1) and Visit 2 (end of 28 day evaluation period)', 'description': 'Participants to complete general neophobia questionnaire at baseline and end of study to compare results'}, {'measure': 'Change in food neophobia', 'timeFrame': 'Visit 1 (Day 1) and Visit 2 (end of 28 day evaluation period)', 'description': 'Participants to complete food neophobia questionnaire at baseline and end of study to compare results'}, {'measure': 'Nutritional suitability: change Phenylalanine levels', 'timeFrame': 'Visit 1 until visit 2 (day 28)', 'description': "PKU express plus' nutritional suitability will be assessed by evaluating Phenylalanine levels recorded as part of routine care"}, {'measure': 'Nutritional suitability: change Tyrosine levels', 'timeFrame': 'Visit 1 until visit 2 (day 28)', 'description': "PKU express plus' nutritional suitability will be assessed by evaluating Tyrosine levels recorded as part of routine care"}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Phenylketonurias', 'PKU', 'Homocystinuria', 'Maple Syrup Urine Disease', 'Hereditary Tyrosinemia', 'Glutaric Acidemia I']}, 'descriptionModule': {'briefSummary': 'A prospective, open label, acceptability study to evaluate PKU, MSUD, HCU, TYR and GA express plus in the dietary management of 40 patients with IEM. The following parameters will be assessed: adherence to prescribed dietary intakes, palatability, usability, gastrointestinal tolerance, clinically relevant routine biochemical parameters, timeframe to transition and contribution of the express plus range to overall protein substitute intake over a 28 day period.', 'detailedDescription': "This is a prospective acceptability study of the express plus range in 40 participants aged at least three years of age for the dietary management of IEM (PKU, MSUD, HCU, TYR and GA ).\n\nThe study will involve a Transition Period where patients will build-up to at least one sachet of express plus per day. During the Transition Period, daily intake of express plus and the patient's other PS will be recorded, including the time taken to consume.\n\nThe Transition Period will last a maximum of 6 weeks, after which the patient will enter a 28-day Evaluation Period. During the Evaluation Period, patients will continue to record intakes, as well as GI tolerance and a final evaluation of the product's palatability and usability. Some patients, likely adults, will not require a transition from their original protein substitute to at least one sachet of express plus. These patients can enter the Evaluation Period directly.\n\nThe end of the 4-week Evaluation Period is defined as the participant's End of Study. Following this, participants will be followed up as per standard of care. Some of this standard of care data may be relayed to the sponsor for a maximum of 26 weeks. This will last for a maximum of 26 weeks and will involve the collection of routine phe and tyrosine levels, as well as amount of PS prescribed and taken. Information will also be collected from patients regarding the reasons for the success or indeed failure of transition to PKU express plus. This data will come from routine clinical contact and will be recorded by the HCP, rather than by the patient."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'minimumAge': '3 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Diagnosis of PKU or associated disorder for example, Tetrahydrobiopterin (BH4) deficiency, requiring a low protein diet and Phe-free L-amino acid supplements (protein substitute).\n* Established on PKU express or an equivalent protein substitute\n* In the opinion of the study investigator, the participant is able to take the study product and meets at least one of the following criteria:\n\n 1. taking an age inappropriate protein substitute\n 2. struggling with adherence to current protein substitute\n 3. delayed in transitioning\n* Aged 3 years and above\n* Willingly given, written, informed consent from patient or parent/guardian.\n* Willingly given, written assent (if appropriate).\n\nExclusion Criteria:\n\n* Diagnosis of persistent hyperphenylalaninaemia, or mild PKU not requiring dietary intervention with a low protein diet and protein substitute.\n* Patients who are tube-fed.\n* Individuals, who in the opinion of the investigator, are unable to comply with the requirements of the protocol.\n* Any co-morbidity/condition which in the opinion of the Investigator, would preclude participation in the study.\n* Patients who are currently participating in, plan to participate in, or have participated in an interventional investigational drug, food or medical device trial within 30 days prior to screening.\n* Use of additional macro/micronutrient supplements during the study period, unless clinically indicated and prescribed by the investigator (must be recorded in patient case record file).\n* Women who are pregnant / breastfeeding at the start of the study or planning to become pregnant during the study period. (N.B.: Women who become pregnant unexpectedly during this study may, in consultation with their doctor, continue on the study's dietary product if they wish but will not have any investigations that would not normally be carried out during pregnancy.)\n* Those with allergies to fish, milk or soya."}, 'identificationModule': {'nctId': 'NCT05051657', 'acronym': 'express plus', 'briefTitle': 'Evaluation of the Express Plus Range', 'organization': {'class': 'INDUSTRY', 'fullName': 'Vitaflo International, Ltd'}, 'officialTitle': 'A Study To Evaluate The Acceptability Of the Express Plus Range, Foods For Special Medical Purposes (FSMP), In Children And Adults With Inborn Errors of Metabolism (IEM)', 'orgStudyIdInfo': {'id': 'MCT-EXPP-2019-05-21'}, 'secondaryIdInfos': [{'id': '281995', 'type': 'OTHER', 'domain': 'IRAS'}, {'id': '20/YH/0248', 'type': 'OTHER', 'domain': 'Sheffield Research Ethics Committee'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'express pus range (PKU, MSUD, HCU, TYR and GA)', 'description': 'express plus to be transitioned onto over a maximum of 6 weeks and then incorporated into each participants usual diet for 28 days. Amount taken and frequency to be determined by dietitian.', 'interventionNames': ['Dietary Supplement: PKU express plus']}], 'interventions': [{'name': 'PKU express plus', 'type': 'DIETARY_SUPPLEMENT', 'description': 'PKU express plus is a powdered protein substitute for the dietary management of PKU. It is formulated in a variety of flavours to provide a convenient, low volume, lower calorie, pre-measured protein substitute, containing a full micronutrient profile.', 'armGroupLabels': ['express pus range (PKU, MSUD, HCU, TYR and GA)']}]}, 'contactsLocationsModule': {'locations': [{'zip': 'BT12 6BA', 'city': 'Belfast', 'country': 'United Kingdom', 'facility': 'Royal Belfast Hospital for Sick Children', 'geoPoint': {'lat': 54.59682, 'lon': -5.92541}}, {'zip': 'B15 2TG', 'city': 'Birmingham', 'country': 'United Kingdom', 'facility': "Birmingham Women's and Children's Hospital", 'geoPoint': {'lat': 52.48142, 'lon': -1.89983}}, {'zip': 'BS2 8BJ', 'city': 'Bristol', 'country': 'United Kingdom', 'facility': 'Bristol Royal Hospital for Children', 'geoPoint': {'lat': 51.45523, 'lon': -2.59665}}, {'zip': 'G12 0XH', 'city': 'Glasgow', 'country': 'United Kingdom', 'facility': 'Greater Glasgow and Clyde NHS Foundation Trust', 'geoPoint': {'lat': 55.86515, 'lon': -4.25763}}, {'zip': 'WC1N 3JH', 'city': 'London', 'country': 'United Kingdom', 'facility': 'Great Ormond Street Hospital for Children', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'NG7 2UH', 'city': 'Nottingham', 'country': 'United Kingdom', 'facility': "Nottingham Children's Hospital", 'geoPoint': {'lat': 52.9536, 'lon': -1.15047}}], 'overallOfficials': [{'name': 'Anita MacDonald', 'role': 'STUDY_DIRECTOR', 'affiliation': "Birmingham Women's and Children's Hospital"}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO', 'description': 'No plans to share IPD'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Vitaflo International, Ltd', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}